0.24Open0.30Pre Close3 Volume902 Open Interest20.00Strike Price72.00Turnover56.86%IV5.14%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier5DDays to Expiry0.24Extrinsic Value100Contract SizeAmericanOptions Type-0.2680Delta0.2235Gamma83.32Leverage Ratio-0.0436Theta-0.0009Rho-22.33Eff Leverage0.0085Vega
Schrodinger Stock Discussion
bringing stock back to 30+
$Exscientia (Delisted) (EXAI.US)$ $Recursion Pharmaceuticals (RXRX.US)$ $NVIDIA (NVDA.US)$
Schrödinger Reports Third Quarter 2024 Financial Results
Schrödinger (SDGR) reported Q3 2024 financial results with total revenue of $35.3 million, down from $42.6 million in Q3 2023. Software revenue increased 10% to $31.9 million, while drug discovery revenue decreased to $3.4 million. The company announced a new collaboration with Novartis, receiving $150 million upfront with potential milestone payments up to $2.3 billion. Operating expenses rose to $86.2 millio...
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
Schrödinger to receive $150 million upfront and eligible to receive up to approximately $2.3 billion in milestone payments plus royalties
Expanded multi-year software agreement enables technology deployment at significant scale across Novartis's global research organization
Schrödinger to host third quarter 2024 financial results webcast today at 8:00 a.m. ET
Schröd...
$Schrodinger (SDGR.US)$
$Schrodinger (SDGR.US)$
all informatics 15% up tomorrow will be SDGR
$Recursion Pharmaceuticals (RXRX.US)$
$Exscientia (Delisted) (EXAI.US)$
$Schrodinger (SDGR.US)$
$Recursion Pharmaceuticals (RXRX.US)$
another silent killer going to blast soon 28
$Schrodinger (SDGR.US)$ AI + Drug Discovery
Bullish on Bioinfoematics..Can cross 100 by next year
Google Deepmind founder shares Nobel prize in chemistry for AI that unlocks the shape of proteins
No comment yet